Skip to main content

Table 3 Regression analysis by disease

From: Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry

 

RA

AS

PsA

OR

95% CI

P value

OR

95% CI

P value

OR

95% CI

P value

Female sex

1.40

(0.16–12.54)

0.765

0.52

(0.16–1.68)

0.276

0.64

(0.30–1.33)

0.241

Age

1.02

(0.97–1.06)

0.450

0.95

(0.91–0.99)

0.016

1.00

(0.97–1.04)

0.822

TNF-i

0.41

(0.08–1.97)

0.265

-

-

-

-

-

-

Smoking (ref smoker)

Non-smoker

2.53

(0.29–22.19)

0.401

0.34

(0.09–1.22)

0.099

1.66

(0.57–5.08)

0.371

Ex-smoker

1.43

(0.08–25.78)

0.807

   

0.67

(0.07–6.23)

0.723

Order of treatment

3.74

(0.95–14.71)

0.06

0.84

(0.25–2.74)

0.767

1.53

(0.69–3.42)

0.298

Disease duration

0.98

(0.90–1.07)

0.649

0.94

(0.86–1.04)

0.228

0.99

(0.93–1.05)

0.778

ACPA (ref negative)

Positive

0.11

(0.02–0.53)

0.006

-

-

-

-

-

-

HLA B27 (ref negative)

Positive

-

-

-

0.51

(0.15–1.78)

0.290

1.16

(0.39–3.47)

0.786

Time on treatment with the previous biologic agent

1.03

(1.02–1.05)

 < 0.001

   

1.01

(1.00–1.02)

0.005

Year of discontinuation of treatment

0.88

(0.73–1.06)

0.178

0.90

(0.80–1.02)

0.11

0.99

(0.90–1.08)

0.787

  1. OR Odds ratio, 95% CI 95% confidence interval, TNF-i Tumor necrosis factor alfa inhibitor, RA Rheumatoid arthritis, AS Ankylosing spondylitis, PsA Psoriatic arthritis, RF Rheumatoid factor, ACPA Anti-citrullinated peptide antibody
  2. There were no ex-smokers for AS